Biofabrication, published by IOP Publishing Ltd, stands at the forefront of the interdisciplinary fields of biochemistry, bioengineering, biomaterials, biomedical engineering, biotechnology, and miscellaneous medicine. Since its inception in 2009, this prestigious journal has secured its position within the Q1 category across multiple disciplines as of 2023, reflecting its high impact and significant contribution to advancing research in these domains. With ranks such as #19 in biochemistry and #10 in biomaterials according to Scopus, it showcases groundbreaking studies and innovative methodologies that are crucial for the evolution of biofabrication technologies. Authored by leading researchers and professionals, the journal publishes articles that explore the synthesis, characterization, and application of biomaterials, providing valuable insights for both academic researchers and industry practitioners. The impact factor of the journal, combined with its rigorous peer-review process, guarantees high-quality content that pushes the boundaries of knowledge and technology. Researchers and students engaged in these dynamic fields will find Biofabrication an indispensable resource for staying abreast of critical developments and emerging trends.

Tissue Engineering Part C: Methods is a prestigious academic journal published by MARY ANN LIEBERT, INC, specializing in the dynamic and rapidly evolving fields of bioengineering and biomedical engineering. With an ISSN of 1937-3384 and E-ISSN 1937-3392, this journal provides a platform for the dissemination of cutting-edge research from 2008 to 2024, showcasing methodologies that advance the science of tissue engineering. Ranked in the second and third quartiles across several categories in 2023, including a notable Q2 in Biomedical Engineering, the journal is recognized for its contributions to the interface of biology and engineering. Additionally, it holds commendable Scopus ranks that highlight its influence and reach within the scientific community. Although it does not offer open access, the journal remains vital for researchers, professionals, and students seeking insightful articles that bridge the gap between theoretical research and practical application in tissues and regenerative medicine. With its rigorous peer-review process and commitment to quality, Tissue Engineering Part C: Methods continues to be an essential resource for those at the forefront of tissue engineering innovations.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.

Stem Cell Research & Therapy is an esteemed international journal published by BMC, specializing in the rapidly advancing fields of stem cell research and regenerative therapies. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that vital research is readily accessible to a global audience. With a significant impact in the scientific community, it holds Q1 quartile rankings in prestigious categories such as Biochemistry, Genetics and Molecular Biology, Cell Biology, and Molecular Medicine, highlighting its critical role in promoting groundbreaking research. The journal’s high Scopus rankings—placing it in the top echelons of its fields—reflect its commitment to publishing high-quality, peer-reviewed studies that advance our understanding of stem cell biology and therapeutic applications. Aimed at researchers, healthcare professionals, and students alike, Stem Cell Research & Therapy is an indispensable resource for those dedicated to the exploration and innovation within this transformative area of science.

Tissue Engineering Part B-Reviews is a premier academic journal published by MARY ANN LIEBERT, INC, focusing on the interdisciplinary field of tissue engineering and regenerative medicine. With an impressive impact factor that places it in the Q1 category across multiple relevant fields—including Biochemistry, Bioengineering, Biomaterials, and Biomedical Engineering—this journal provides a vital platform for researchers and professionals to disseminate cutting-edge findings and comprehensive reviews. Covering a vast scope from 2008 to 2024, the journal is committed to advancing knowledge in the application of engineering principles to biological tissues, making it an indispensable resource for those at the forefront of biomedical innovation. While the journal does not currently offer open access options, its rigorous peer review process ensures high-quality contributions that are essential for academic and practical advancements. The journal's rankings in Scopus reflect its significance, catering to a diverse audience of students, researchers, and practitioners seeking the latest insights in this dynamic field.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

CELL AND TISSUE BANKING, published by Springer, is a prominent journal dedicated to advancing the fields of biomaterials, biomedical engineering, cell biology, and transplantation. With its ISSN 1389-9333 and E-ISSN 1573-6814, the journal plays a crucial role in disseminating high-quality research from its inception in 2000 to its ongoing contributions through 2024. Situated in the Netherlands, it boasts a respectable 2023 impact factor with notable quartile rankings, positioning it within the Q3 category for biomaterials, biomedical engineering, and transplantation, and Q4 for cell biology. Furthermore, its Scopus rankings underscore its relevance and influence, particularly in the fields of medicine and engineering. Although it does not currently offer open access options, the journal remains a vital resource for researchers, professionals, and students alike, fostering innovation and knowledge transfer in the critical areas of cell and tissue sustainability.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.